UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________ Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ to _____________________ Commission File Number: 001-36426 ____________ AquaBounty Technologies, Inc. (Exact name of registrant as spe ...

SBC Medical Group Holdings Announces First Quarter 2025 Financial Results Irvine, Calif., May 15, 2025 (Business Wire) – SBC Medical Group Holdings Incorporated (NASDAQ: SBC, "SBC Medical" or the "Company"), a global owner, operator and provider of management services and products to cosmetic treatment centers, today announced its financial results for the three months ended March 31, 2025. First Quarter 2025 Highlights Yoshiyuki Aikawa, Chairman and Chief Executive Officer of SBC Medical, said, "SBC is act ...

Exhibit 99.1 EBITDA and EBITDA Margin are non-GAAP financial measures. For more information on non-GAAP financial measure, please see the section of "Use of Non-GAAP Financial Measures" and the table captioned "Unaudited Reconciliations of GAAP and Non-GAAP Results." The number of customers takes into account customers of SBC brand clinics, Rize Clinic and Gorilla Clinic, but does not take account customers of AHH Clinics SBC Medical Group Holdings Announces First Quarter 2025 Financial Results 3 The number ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Commission File Number) (I.R.S. Employer Identification No.) CURRENT REPORT (State or other jurisdiction of incorporation or organization) Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 CLOUDASTRUCTURE, INC. (Exact name of registrant as specified in its charter) ___________________________ Delaware 001-42494 87-0690564 FORM 8-K Date of Report (Date of earliest event reported): May 15, 2025 ______________________ ...

财务数据关键指标变化 - 2024年全年运营净亏损约2160万美元，2023年同期约为1680万美元，主要因330万美元的合并相关成本、170万美元的重组成本和150万美元的研发费用增加，被170万美元的一般及行政费用减少所抵消[6] - 2024年研发费用为700万美元，2023年同期约为550万美元；2024年一般及行政费用约为970万美元，2023年约为1140万美元[7] - 截至2024年12月31日，公司现金约260万美元，加上2025年3月私募所得净收益660万美元，预计可支持运营至2025年9月[8] - 2024年公司总资产为5056.2万美元，2023年为435.5万美元；总负债为2833.3万美元，2023年为458.4万美元[17] - 2024年公司净亏损1979.1万美元，2023年为1000.8万美元；综合亏损为1948.9万美元，2023年为1027.7万美元[19] 业务线研发进展 - 公司正在推进下一代精准双功能抗体药物偶联物（ADC）的开发，用于治疗癌症[1][9] - 公司的主要候选药物AKTX - 101在临床前研究中显示出优于当前TROP2 ADC的活性、延长生存期、降低耐药性和更好的耐受性等优势[4] - 2024年11月与Peak Bio完成合并后，公司专注于新型抗癌有效载荷的发现、研发及应用[3] - 公司将继续推进管线，为PH1有效载荷生成更多验证数据，同时开展PH5和PH6新型有效载荷的发现工作[10] 业务线合作策略 - 公司将为AKTX - 101寻找许可/战略合作伙伴[10]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41861 Agriculture & Natural Solutions Acquisition Corporation (Exact name of registrant as specified in its charter) Cayman Isl ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Agriculture & Natural Solutions Acquisition Corporation (Exact name of registrant as specified in its charter) Cayman Islands 98-1591619 (State or other jurisdiction of incorporation) (I.R. ...

Exhibit 99.1 As used in this announcement, non-GAAP net income attributable to the Company's shareholders and non-GAAP basic and diluted net income per share and per ADS are defined to exclude share-based compensation expenses. See the unaudited reconciliation of GAAP and non-GAAP results at the end of this announcement. 1 · Net revenues were RMB28.8 billion (US$4.0 billion), an increase of 7.4% compared with the same quarter of 2024. · Games and related value-added services net revenues were RMB24.0 billio ...

FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______, 20___, to _____, 20___. Commission File Number 001-41272 HeartCore Enterprises, Inc. (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdict ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the transition period from to Commission file number 001-36548 ATARA BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) | Delaware | 46-0920988 | | --- | --- | | (State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification No.) | | 1280 Rancho Conejo Boulevard | | | Thousand Oaks, CA | 91320 | | (Address of Principal Executive Offices) | (Zip Code) | | Registrant's Teleph ...